XML 49 R39.htm IDEA: XBRL DOCUMENT
v3.19.1

Non-controlling Interest (Details Textual) - USD ($) |  | 3 Months Ended
--- | --- | ---
Sep. 05, 2018 | Mar. 31, 2019 | Mar. 31, 2018
Noncontrolling Interest [Line Items] |  |  |
Related Party Transaction, Expenses from Transactions with Related Party | $ 441,000 |  |
Research and Development Expense | $ 16,000 | $ 2,418,000 | $ 3,370,000
Synthetic Biomics Inc [Member] |  |  |
Noncontrolling Interest [Line Items] |  |  |
Additional Number Of Common Stock To Be Issued | 2,420,000 |  |
Cedars-Sinai Medical Center [Member] |  |  |
Noncontrolling Interest [Line Items] |  |  |
Number Of Common Stock To Be Issued | 50,000 | 50,000 |
Fair Value of Shares Issued | $ 285,000 |  |
Cedars-Sinai Medical Center [Member] | Synthetic Biomics Inc [Member] |  |  |
Noncontrolling Interest [Line Items] |  |  |
Additional Number Of Common Stock To Be Issued |  | 2,420,000 |
Number Of Common Stock To Be Held By Related Party | 7,480,000 | 7,480,000 |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 17.00% | 17.00% |

X
- Definition The additional number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_AdditionalNumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount represents the fair value of shares issued. + References No definition available. + Details
Name: | syn_FairValueOfSharesIssued
Namespace Prefix: | syn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The additional number of common stock to be held by the related party under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeHeldByRelatedParty
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of common stock to be issued under stock purchase agreement. + References No definition available. + Details
Name: | syn_NumberOfCommonStockToBeIssued
Namespace Prefix: | syn_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_MinorityInterestLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_OwnershipAxis=syn_SyntheticBiomicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |